Drugs fail to meet hormone targets in control of rare growth disorder

Over a quarter of UK patients treated for growth hormone-producing tumours do not achieve 'safe' growth hormone (GH) levels, according to a 30 year UK multi-centre study of clinical management of the rare disease acromegaly. The findings show that drugs to control acromegaly often fail to bring the disease completely under control in routine clinical practice.